Attendee search 

Kairos Therapeutics has developed a proprietary next generation antibody-drug conjugate (ADC) platform based on novel toxin, linker and site-specific conjugation technology. Kairos has demonstrated superior pre-clinical in-vivo efficacy over T-DM1. Further pre-clinical studies demonstrate Kairos’ ADCs have superior tolerability and therapeutic index, compared to other leading platforms which may lead to greater clinical efficacy. Through key partnerships, Kairos is developing a novel therapeutic pipeline and is out-licensing its ADC platform to companies seeking access to state-of-the-art technology.  

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick NJ with an Innovation Center in Cambridge MA. The firm invests in a variety of fields within the life science sector including medical devices. J&J?s medical device investments are highly varied in both size and structure, the structure may involve milestone payments or may be an equity investment. J&J is interested in early stage medical device companies located globally.

NSF Health Sciences offers clinical, regulatory, and quality consulting services across the total product lifecycle for innovative medical device, pharmaceutical, and biotechnology companies.  We specialize in helping companies balance FDA and worldwide regulatory requirements with their business needs. 

Healthcare Software focusing in on Mental health & Addictions. The main goal is to place these individuals on a path to recovery.

TREAT product line is commercially available as an EHR serving the unique needs of community behavioral health, rehabilitation, and other community-based providers. The design of our system is centered on a client-centered recovery model principle with best practice assessments linked to an interdisciplinary plan of care which is at the core of our methodology. TREAT’s modules create a record of client care that functions at multiple levels and builds upon itself. From assessments, to care planning, to documentation, to decision support, TREAT provides an integrated solution centered on client care.

Assessment Tools

Our TREAT product has a catalog of over 120 different assessment tools, and can be customized to include new tools upon request. Assessments are linked with our Interdisciplinary Plan of Client Care (IPCC) and Progress Notes modules to offer a truly integrated approach to patient care.

Humabs BioMed is a profitable Swiss biotech company that is discovering and developing nature-selected human monoclonal antibodies using proprietary platforms. 

Humabs is currently focusing on the development of human antibodies to fight infectious diseases. Additional indications are being targeted at the discovery research stage.

Humabs has already achieved four major licensing deals with Pharmaceutical companies generating significant revenues in the form of near term revenues, as well as a stream of longer term milestones and royalties. Two of these programs are in clinical development phases.

Humabs is seeking additional investments to allow the company to bring selected programs into clinical research on its own, thus significantly increasing the added value.

SENS Research Foundation is based in Mountain View, CA. The foundation provides grants for research into rejuvenation biotechnologies that prevent or reverse age-related tissue damage. Historically grants have ranged from $40,000 to $200,000 although this range may change in the future. Grants are available to researchers worldwide. SENS requests that grants not be used to cover overhead/facilities costs. At present, 15 projects are being supported.